HU
Humacyte, Inc.
HUMAW · NASDAQ
$0.00 -99.09% (-$0.23)
1M -87.14%
Market Cap $2.53M
P/E Ratio -
Div. Yield -
ROE 938.20%
Piotroski F-Score Weak
2/9Valuation
100 /100
Cheap P/B 0.08x
P/S 1.19x
P/FFO N/A
Growth
49 /100
Stable Book val. growth 70.15%
Rev. growth 9.20%
FCF growth N/A
Profitability
0 /100
Weak Op. margin 5,240.78%
Gross margin 666.81%
FCF margin 4,599.72%
Quality
0 /100
Poor ROA 70.05%
ROIC 89.17%
Asset turnover 0.02x
Debt
30 /100
High Int. coverage -8.39x
Debt/Equity 2.12x
Current ratio 6.21x
Stability
1 /100
Unstable Profitable years 0
Beta 2.43x
EPS volatility 477.33%
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about HUMAW
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Laura E. Niklason
Employees
184
Headquarters
Durham
Upcoming events
06 NOV
Earnings
Upcoming earnings report